Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 24, 2020 07:00 ET | Source: Mateon Therapeutics, Inc.

MATEON IS SELECTED BY IBM WATSON HEALTH FOR THE USE OF IBM CLINICAL DEVELOPMENT SOLUTION AT NO COST FOR PHASE II CLINICAL TRIAL OF OT-101 FOR COVID-19

Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates AGOURA HILLS,...